Literature DB >> 21480865

Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.

O Gomez1, A Sanchez-Rodriguez, Mqu Le, C Sanchez-Caro, F Molina-Holgado, E Molina-Holgado.   

Abstract

BACKGROUND AND
PURPOSE: The endogenous cannabinoid system participates in oligodendrocyte progenitor differentiation in vitro. To determine the effect of synthetic cannabinoids on oligodendrocyte differentiation, we exposed differentiating cultures of oligodendrocytes with cannabinoid CB(1), CB(2) and CB(1)/CB(2) receptor agonists and antagonists. The response of the PI3K/Akt and the mammalian target of rapamycin (mTOR) signalling pathways were studied as effectors of cannabinoid activity. EXPERIMENTAL APPROACH: Purified oligodendrocyte progenitor cells (OPC) obtained from primary mixed glial cell cultures were treated for 48 h with CB(1), CB(2) and CB(1) /CB(2) receptor agonists (ACEA, JWH133 and HU210, respectively) in the presence or absence of the antagonists AM281 (CB(1) receptor) and AM630 (CB(2) receptor). Moreover, inhibitors of the phosphatidylinositol 3-kinase (PI3K)/Akt and mTOR pathways (LY294002 and rapamycin, respectively) were used to study the involvement of these pathways on cannabinoid-induced OPC maturation. KEY
RESULTS: ACEA, JWH133 and HU-210 enhanced OPC differentiation as assessed by the expression of stage specific antigens and myelin basic protein (MBP). Moreover, this effect was blocked by the CB receptor antagonists. ACEA, JWH133 and HU210 induced a time-dependent phosphorylation of Akt and mTOR, whereas the inhibitors of PI3K/Akt (LY294002) or of mTOR (rapamycin) reversed the effects of HU-210 on oligodendrocyte differentiation and kinase activation. CONCLUSIONS AND IMPLICATIONS: Activation of cannabinoid CB(1) or CB(2) receptors with selective agonists accelerated oligodendrocyte differentiation through the mTOR and Akt signalling pathways.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480865      PMCID: PMC3165960          DOI: 10.1111/j.1476-5381.2011.01414.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Cell death and control of cell survival in the oligodendrocyte lineage.

Authors:  B A Barres; I K Hart; H S Coles; J F Burne; J T Voyvodic; W D Richardson; M C Raff
Journal:  Cell       Date:  1992-07-10       Impact factor: 41.582

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  Immunochemical measurement of myelin basic protein in developing rat brain: an index of myelin synthesis.

Authors:  S R Cohen; M Guarnieri
Journal:  Dev Biol       Date:  1976-03       Impact factor: 3.582

4.  Atypical location of cannabinoid receptors in white matter areas during rat brain development.

Authors:  J Romero; E Garcia-Palomero; F Berrendero; L Garcia-Gil; M L Hernandez; J A Ramos; J J Fernández-Ruiz
Journal:  Synapse       Date:  1997-07       Impact factor: 2.562

5.  Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

Authors:  M Bouaboula; C Poinot-Chazel; B Bourrié; X Canat; B Calandra; M Rinaldi-Carmona; G Le Fur; P Casellas
Journal:  Biochem J       Date:  1995-12-01       Impact factor: 3.857

6.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor.

Authors:  W A Devane; L Hanus; A Breuer; R G Pertwee; L A Stevenson; G Griffin; D Gibson; A Mandelbaum; A Etinger; R Mechoulam
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.

Authors:  T Sugiura; S Kondo; A Sukagawa; S Nakane; A Shinoda; K Itoh; A Yamashita; K Waku
Journal:  Biochem Biophys Res Commun       Date:  1995-10-04       Impact factor: 3.575

8.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

Authors:  R Mechoulam; S Ben-Shabat; L Hanus; M Ligumsky; N E Kaminski; A R Schatz; A Gopher; S Almog; B R Martin; D R Compton
Journal:  Biochem Pharmacol       Date:  1995-06-29       Impact factor: 5.858

9.  Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development.

Authors:  F Berrendero; L García-Gil; M L Hernández; J Romero; M Cebeira; R de Miguel; J A Ramos; J J Fernández-Ruiz
Journal:  Development       Date:  1998-08       Impact factor: 6.868

10.  Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.

Authors:  K D McCarthy; J de Vellis
Journal:  J Cell Biol       Date:  1980-06       Impact factor: 10.539

View more
  41 in total

1.  CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.

Authors:  Javier Palazuelos; Zaira Ortega; Javier Díaz-Alonso; Manuel Guzmán; Ismael Galve-Roperh
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

2.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

3.  A Basal Tone of 2-Arachidonoylglycerol Contributes to Early Oligodendrocyte Progenitor Proliferation by Activating Phosphatidylinositol 3-Kinase (PI3K)/AKT and the Mammalian Target of Rapamycin (MTOR) Pathways.

Authors:  Oscar Gomez; Maria A Sanchez-Rodriguez; Silvia Ortega-Gutierrez; Henar Vazquez-Villa; Carmen Guaza; Francisco Molina-Holgado; Eduardo Molina-Holgado
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

Review 4.  Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells.

Authors:  Moises Garcia-Arencibia; Eduardo Molina-Holgado; Francisco Molina-Holgado
Journal:  Br J Pharmacol       Date:  2018-06-22       Impact factor: 8.739

5.  2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Authors:  Ana Feliú; Itziar Bonilla Del Río; Francisco Javier Carrillo-Salinas; Gloria Hernández-Torres; Leyre Mestre; Nagore Puente; Silvia Ortega-Gutiérrez; Maria L López-Rodríguez; Pedro Grandes; Miriam Mecha; Carmen Guaza
Journal:  J Neurosci       Date:  2017-07-27       Impact factor: 6.167

Review 6.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

7.  Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.

Authors:  Joseph E Henriquez; Michael D Rizzo; Matthias A Schulz; Robert B Crawford; Peter Gulick; Norbert E Kaminski
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

8.  Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formation.

Authors:  Yan Yang; Haibo Wang; Jie Zhang; Fucheng Luo; Karl Herrup; James A Bibb; Richard Lu; Robert H Miller
Journal:  Dev Biol       Date:  2013-04-10       Impact factor: 3.582

Review 9.  Endocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development.

Authors:  Javier Díaz-Alonso; Manuel Guzmán; Ismael Galve-Roperh
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

Review 10.  Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

Authors:  Jane M Rodgers; Andrew P Robinson; Stephen D Miller
Journal:  Discov Med       Date:  2013-08       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.